SciSparc (SPRC) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SciSparc is the larger company by market cap ($2.6 million vs $2.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRC | VRAX |
|---|---|---|
| Share price | $4.47 | $1.87 |
| Market cap | $2.60M | $2.52M |
| 1-day change | +0.90% | -6.03% |
| P/E ratio (TTM) | 0.02 | — |
| EPS (TTM) | $248.24 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.65 | $21.75 |
| 52-week low | $2.98 | $1.81 |
| Distance from 52-week high | -89.76% | -91.40% |
| Average volume | 179.62K | 650.11K |
| Shares outstanding | 580.97K | 1.34M |
| Employees | 3 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
SPRC vs VRAX FAQ
Which is bigger, SciSparc or Virax Biolabs Group?
SciSparc (SPRC) is larger, with a market capitalization of $2.60M compared with $2.52M for Virax Biolabs Group (VRAX).
Are SciSparc and Virax Biolabs Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for SciSparc and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Virax Biolabs Group.